Hutchmed Climbs After On Initiating Hmpl: A830 global trial in solid tumors
28/09/2026 04:53
BUZZ-HUTCHMED climbs after on initiating HMPL-A830 global trial in solid tumors ** Shares of HUTCHMED (China) 0013.HK climb 2.6% to HK$22.5, on course for the biggest one-day pct gain since September 21
** Stock set to snap two straight sessions of fall
** The pharmaceuticals manufacturer says it has initiated the Phase Ia part of a global clinical trial of HMPL-A830 in patients with unresectable, advanced or metastatic solid tumors
** HUTCHMED says its unit, on September 3, entered into an exclusive development and license agreement with a GSK plc unit, granting the GSK unit worldwide rights to develop and commercialize HMPL-A830 with HUTCHMED responsible for the global Phase І development program of HMPL-A830
** YTD, Hong Kong stock up 7.5%, Hang Seng Biotech Index .HSBIO up 11.6%
(Reporting by Donny Kwok)